- Trials with a EudraCT protocol (52)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
52 result(s) found for: Congenital Hemolytic Anemia.
Displaying page 1 of 3.
EudraCT Number: 2020-004225-22 | Sponsor Protocol Number: CSEG101A2401B | Start Date*: 2021-05-03 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: An Open-label, Multi-center, Phase IV, Rollover Study for Patients with Sickle Cell Disease who have Completed a Prior Novartis-Sponsored Crizanlizumab Study | ||||||||||||||||||
Medical condition: Sickle Cell Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) IT (Ongoing) FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000583-15 | Sponsor Protocol Number: 60858 | Start Date*: 2017-08-11 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Randomized controlled trial on the use of EPO to reduce top-up transfusions in neonates with red blood cell alloimmunization treated with intrauterine transfusions | |||||||||||||
Medical condition: Hemolytic disease of the newborn due to red blood cell alloimmunization | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004568-37 | Sponsor Protocol Number: INV543 | Start Date*: 2018-11-30 | ||||||||||||||||
Sponsor Name:Nova Laboratories Limited | ||||||||||||||||||
Full Title: A prospective open label, pharmacokinetic study of an oral hydroxyurea solution in children with sickle cell anemia | ||||||||||||||||||
Medical condition: Sickle Cell Anaemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004045-25 | Sponsor Protocol Number: GBT440-034 | Start Date*: 2018-04-17 | |||||||||||
Sponsor Name:Global Blood Therapeutics, Inc. | |||||||||||||
Full Title: An Open Label Extension Study of Voxelotor (GBT440) Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003601-66 | Sponsor Protocol Number: CSEG101ANL01T | Start Date*: 2021-07-14 | |||||||||||
Sponsor Name:Amsterdam UMC - AMC | |||||||||||||
Full Title: The Effect of Crizanlizumab on Cerebral Perfusion and Oxygenation in Sickle Cell Patients | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001585-36 | Sponsor Protocol Number: AMC_SMILE_1.0 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Amsterdam UMC | |||||||||||||
Full Title: EffectS of L-glutaMIne on oxIdative stress, sickLE erythrocyte viability, inflammation and endothelial activity in sickle cell disease (SMILE trial) | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001351-13 | Sponsor Protocol Number: APHP201133 | Start Date*: 2021-11-26 | |||||||||||
Sponsor Name:Assistance Publique des Hôpitaux de Paris(AP-HP) | |||||||||||||
Full Title: Interest of famotidine in reducing endothelial expression of P-selectin in children with sickle cell disease: pilot study, single-center, prospective, non-comparative | |||||||||||||
Medical condition: major sickle cell syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004958-42 | Sponsor Protocol Number: MOM-M281-003 | Start Date*: 2019-01-11 | |||||||||||
Sponsor Name:Momenta Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease ... | |||||||||||||
Medical condition: Early onset Severe Hemolytic Disease of the fetus and newborn (HDFN) | |||||||||||||
|
|||||||||||||
Population Age: In utero, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) NL (Ongoing) SE (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003485-39 | Sponsor Protocol Number: NN7533-4470 | Start Date*: 2022-07-19 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease | |||||||||||||
Medical condition: Sickle cell disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002101-19 | Sponsor Protocol Number: CACZ885X2206 | Start Date*: 2016-11-22 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric and young adult pa... | |||||||||||||
Medical condition: Sickle cell anemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003608-38 | Sponsor Protocol Number: CSEG101A2203 | Start Date*: 2019-12-04 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients ≥ ... | ||||||||||||||||||
Medical condition: Sickle Cell Disease; Sickle Cell Nephropathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) ES (Ongoing) FR (Completed) IT (Prematurely Ended) NL (Completed) IE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-002173-26 | Sponsor Protocol Number: VX21-CTX001-151 | Start Date*: 2021-10-05 | |||||||||||
Sponsor Name:VERTEX PHARMACEUTICALS INCORPORATED | |||||||||||||
Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease | |||||||||||||
Medical condition: Severe Sickle Cell Disease (SCD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) DE (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005289-32 | Sponsor Protocol Number: GBT2104-133 | Start Date*: 2021-11-10 | |||||||||||
Sponsor Name:Global Blood Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004839-25 | Sponsor Protocol Number: BO42451 | Start Date*: 2021-08-18 | ||||||||||||||||
Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | ||||||||||||||||||
Full Title: A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) I... | ||||||||||||||||||
Medical condition: Sickle Cell Disease (SCD); vaso-occlusive episodes in SCD | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004840-27 | Sponsor Protocol Number: BO42452 | Start Date*: 2021-06-21 | ||||||||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE IB RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISOD... | ||||||||||||||||||
Medical condition: Sickle cell disease (SCD); vaso-occlusive episodes (VOE) in SCD | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) IT (Ongoing) ES (Ongoing) NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005161-20 | Sponsor Protocol Number: SCC01 | Start Date*: 2012-02-14 | |||||||||||
Sponsor Name:University College Dublin Clinical Research Centre | |||||||||||||
Full Title: A Randomised Controlled Double-Blind Trial of Intranasal Fentanyl versus Intravenous Morphine in the Emergency Department Treatment of Severe Painful Sickle Cell Crises in Children | |||||||||||||
Medical condition: Severe Painful Sickle Cell Disease Crises in Children | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003144-76 | Sponsor Protocol Number: GBT440-038 | Start Date*: 2020-01-10 | |||||||||||
Sponsor Name:Global Blood Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label Extension Study of Voxelotor Administered Orally to Pediatric Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000597-31 | Sponsor Protocol Number: CICL670A 0109E1 | Start Date*: 2008-06-02 |
Sponsor Name:Novartis Pharmaceuticals UK Ltd | ||
Full Title: A one year open label, non comparative extension to a randomised, multicentre, phase II study to evaluate the asfety, tolerability, pharmacokinetics and effects on iron concentration of repeated do... | ||
Medical condition: Sickle cell disease patients with transfusional hemosiderosis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001838-34 | Sponsor Protocol Number: GBT440-029 | Start Date*: 2019-11-05 | |||||||||||
Sponsor Name:Global Blood Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients with Sickle Cell Disease | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005072-34 | Sponsor Protocol Number: VIT-2763-SCD-202 | Start Date*: 2021-07-26 | |||||||||||
Sponsor Name:Vifor (International) Inc. | |||||||||||||
Full Title: A Phase 2a, double-blind, randomised, placebo controlled, efficacy, and safety study of multiple doses of VIT-2763 in subjects with sickle cell disease (ViSion Serenity) | |||||||||||||
Medical condition: Sickle cell disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.